TW202309068A - 偵測ａａｖ之方法 - Google Patents

偵測ａａｖ之方法 Download PDF

Info

Publication number
TW202309068A
TW202309068A TW111138258A TW111138258A TW202309068A TW 202309068 A TW202309068 A TW 202309068A TW 111138258 A TW111138258 A TW 111138258A TW 111138258 A TW111138258 A TW 111138258A TW 202309068 A TW202309068 A TW 202309068A
Authority
TW
Taiwan
Prior art keywords
aav
amino acid
aav2
particle
capsid
Prior art date
Application number
TW111138258A
Other languages
English (en)
Chinese (zh)
Inventor
曉英 金
凱瑟琳 奧瑞爾登
琳 劉
曉葵 張
Original Assignee
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202309068(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商健臻公司 filed Critical 美商健臻公司
Publication of TW202309068A publication Critical patent/TW202309068A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111138258A 2016-08-15 2017-08-15 偵測ａａｖ之方法 TW202309068A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
US62/375,314 2016-08-15

Publications (1)

Publication Number Publication Date
TW202309068A true TW202309068A (zh) 2023-03-01

Family

ID=59762045

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111138258A TW202309068A (zh) 2016-08-15 2017-08-15 偵測ａａｖ之方法
TW106127648A TWI781953B (zh) 2016-08-15 2017-08-15 偵測ａａｖ之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106127648A TWI781953B (zh) 2016-08-15 2017-08-15 偵測ａａｖ之方法

Country Status (22)

Country Link
US (5) US11698377B2 (enExample)
EP (2) EP3851449A1 (enExample)
JP (3) JP7021191B2 (enExample)
KR (5) KR102922101B1 (enExample)
CN (2) CN118688363A (enExample)
AU (2) AU2017312951B2 (enExample)
CA (1) CA3033856A1 (enExample)
CL (2) CL2019000392A1 (enExample)
CR (1) CR20190127A (enExample)
CY (1) CY1124364T1 (enExample)
DK (1) DK3497207T3 (enExample)
ES (1) ES2863674T3 (enExample)
HU (1) HUE053747T2 (enExample)
IL (3) IL264819B2 (enExample)
MA (1) MA55748A (enExample)
MX (2) MX2019001938A (enExample)
PH (1) PH12019500316A1 (enExample)
SG (2) SG10201913002QA (enExample)
TN (1) TN2019000047A1 (enExample)
TW (2) TW202309068A (enExample)
WO (1) WO2018035059A1 (enExample)
ZA (2) ZA201900945B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
HUE053747T2 (hu) 2016-08-15 2021-07-28 Genzyme Corp Eljárások AAV kimutatására
RS65241B1 (sr) * 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3768695A4 (en) * 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
IL276859B2 (en) * 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3762500A1 (en) * 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US11391707B2 (en) * 2018-07-27 2022-07-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
US12195745B2 (en) * 2018-08-21 2025-01-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
WO2020086893A1 (en) 2018-10-25 2020-04-30 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
ES2965341T3 (es) * 2019-04-11 2024-04-12 Regenxbio Inc Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes
US11841352B2 (en) * 2019-07-31 2023-12-12 Thermo Finnigan Llc Determination and correction of retention time and mass/charge shifts in LC-MS experiments
EP4085255A1 (en) * 2020-01-03 2022-11-09 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
WO2021155137A1 (en) 2020-01-29 2021-08-05 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
US20220268783A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2022224965A1 (ja) * 2021-04-20 2022-10-27 株式会社ユニバーサル・バイオサンプリング 検体保持カード及びそれを用いた検体の検査方法
JP2024525686A (ja) * 2021-07-12 2024-07-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａａｖカプシド比を決定するための液体クロマトグラフィーアッセイ
CA3225360A1 (en) * 2021-07-12 2023-01-19 Victoria COTHAM Online native mass spectrometry methods for assaying viral particles
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
EP4462114A4 (en) * 2022-01-06 2025-04-16 FUJIFILM Corporation Method and kit for identifying sugar-bound amino acid site in protein
US20250110119A1 (en) * 2023-03-03 2025-04-03 Sartorius Bioanalytical Instruments, Inc. Methods for quantitating viral capsids
WO2024263520A1 (en) * 2023-06-19 2024-12-26 Regeneron Pharmaceuticals, Inc. Host cell protein analysis for adeno-associated virus (aav)-based gene therapy
AU2024378556A1 (en) * 2023-11-08 2026-05-21 Oxford Biomedica (Us) Llc Deamidation depleted adeno-associated virus product

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
SI1496944T1 (sl) 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
WO2004049385A2 (en) 2002-11-22 2004-06-10 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2342567A1 (en) 2008-09-19 2011-07-13 Charité Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
JP5956331B2 (ja) 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えａａｖベクターの改良された精製方法
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (ja) * 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
HUE053747T2 (hu) 2016-08-15 2021-07-28 Genzyme Corp Eljárások AAV kimutatására

Also Published As

Publication number Publication date
US20250138024A1 (en) 2025-05-01
JP2024023460A (ja) 2024-02-21
AU2017312951B2 (en) 2024-02-08
ES2863674T3 (es) 2021-10-11
CL2019000392A1 (es) 2019-05-10
JP2019533803A (ja) 2019-11-21
EP3497207A1 (en) 2019-06-19
US12298313B1 (en) 2025-05-13
US20250027951A1 (en) 2025-01-23
EP3851449A1 (en) 2021-07-21
US11698377B2 (en) 2023-07-11
CN118688363A (zh) 2024-09-24
KR20230078834A (ko) 2023-06-02
KR102425289B1 (ko) 2022-07-27
KR20220107327A (ko) 2022-08-02
AU2017312951A1 (en) 2019-04-04
RU2019107207A3 (enExample) 2021-04-29
US20240044910A1 (en) 2024-02-08
EP3497207B1 (en) 2021-01-06
CN110168080A (zh) 2019-08-23
IL264819B2 (en) 2024-10-01
IL264819A (enExample) 2019-04-30
NZ791263A (en) 2025-11-28
IL312792B2 (en) 2026-03-01
NZ791267A (en) 2025-11-28
MX2023009081A (es) 2023-08-08
TWI781953B (zh) 2022-11-01
ZA202101002B (en) 2024-07-31
AU2024200349B2 (en) 2026-05-14
TN2019000047A1 (en) 2020-07-15
JP2022064980A (ja) 2022-04-26
JP7021191B2 (ja) 2022-02-16
CY1124364T1 (el) 2022-07-22
AU2024200349A1 (en) 2024-02-08
BR112019002934A2 (pt) 2019-05-14
IL264819B1 (en) 2024-06-01
KR102538037B1 (ko) 2023-05-30
ZA201900945B (en) 2021-06-30
TW201825898A (zh) 2018-07-16
SG10201913002QA (en) 2020-03-30
US20250147042A1 (en) 2025-05-08
RU2019107207A (ru) 2020-09-15
KR20190039253A (ko) 2019-04-10
MX2019001938A (es) 2019-07-04
CN110168080B (zh) 2024-05-31
SG11201901221YA (en) 2019-03-28
PH12019500316A1 (en) 2019-08-05
IL312792B1 (en) 2025-11-01
WO2018035059A1 (en) 2018-02-22
WO2018035059A9 (en) 2019-03-14
NZ751711A (en) 2025-11-28
CL2019002912A1 (es) 2020-03-06
DK3497207T3 (da) 2021-03-22
KR20260036296A (ko) 2026-03-16
US20210041451A1 (en) 2021-02-11
IL323969A (en) 2025-12-01
IL312792A (en) 2024-07-01
CA3033856A1 (en) 2018-02-22
CR20190127A (es) 2019-06-25
HUE053747T2 (hu) 2021-07-28
KR102738219B1 (ko) 2024-12-05
US12123880B2 (en) 2024-10-22
KR102922101B1 (ko) 2026-02-03
MA55748A (fr) 2022-03-02
KR20240172773A (ko) 2024-12-10

Similar Documents

Publication Publication Date Title
AU2024200349B2 (en) Methods for detecting AAV
RU2771622C2 (ru) Способы выявления aav
HK40056223A (en) Methods for detecting aav
BR122024011768A2 (pt) Métodos para determinar a heterogeneidade de uma partícula de aav
BR122024011758A2 (pt) Partícula de raav, composição farmacêutica, kit e artigo de fabricação compreendendo a mesma, proteína de capsídeo de aav e métodos para otimizar a estabilidade, montagem ou transdução de uma partícula de raav
BR122024011753A2 (pt) Partícula de raav, composição farmacêutica, kit e artigo de fabricação compreendendo a mesma, proteína do capsídeo de aav, métodos para para otimizar a estabilidade, montagem, ou transdução de partículas de raav em uma célula
HK40013370B (zh) 检测aav的方法
HK40009308A (en) Methods for detecting aav
HK40009308B (en) Methods for detecting aav
BR122024011745A2 (pt) Métodos para determinar o sorotipo de uma partícula viral e para determinar a heterogeneidade de um sorotipo de uma partícula viral
BR122024011768B1 (pt) Métodos para detectar modificações pós-traducionais de proteínas virais (vps) em uma preparação de partículas de vírus adeno-associados (aav) e para identificar proteínas virais (vps) desamidadas em uma preparação de partículas de vírus adeno-associado (aav)
BR112019002934B1 (pt) Método para determinar o sorotipo de uma partícula de vírus adenoassociado (aav) e método para determinar o sorotipo de uma partícula viral
BR122024011758B1 (pt) PARTÍCULA DE AAV RECOMBINANTE (rAAV) E COMPOSIÇÃO FARMACÊUTICA